FDA Flags Jeuveau Instagram Post as Misleading, Evolus Shares Drop
EOLS sits 86% above its 52-week low of $3.86.
Summary
The FDA has determined that an Evolus Instagram post promoting Jeuveau is misleading, triggering a selloff in the stock. This is the first regulatory action against the company's marketing for its flagship product. Jeuveau is Evolus's primary revenue driver, so any FDA scrutiny of its promotion could impact sales momentum. The company has not yet issued a response. Investors will watch for any required corrective actions or potential fines.
At the time of this announcement, EOLS was trading at $7.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $474.6M. The 52-week trading range was $3.86 to $9.31. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.